FDA
-
-
-
-
-
-
-
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
-
-
-
-
-
-
-
Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Artelo Biosciences reports positive interim Phase 2 trial results for CACS
-
-
-
-
-
-
-
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results
-
-
-
-
-
-
-
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
-
-
-
-
-
-
-
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium
-
-
-
-
-
-
-
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
-
326,536 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

